EcoDrugPlus

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 4

Ensembl ID : ENSOMYG00000016062
Gene Symbol: CACNG4
1 Cross references
181 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 5

Ensembl ID : ENSOMYG00000024939
Gene Symbol: CACNG5
1 Cross references
178 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 5

Ensembl ID : ENSOMYG00000016058
Gene Symbol: CACNG5
1 Cross references
179 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 8

Ensembl ID : ENSOMYG00000002672
Gene Symbol: CACNG8
1 Cross references
157 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 8

Ensembl ID : ENSOMYG00000048250
Gene Symbol: CACNG8
1 Cross references
157 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 A

Ensembl ID : ENSOMYG00000057759
Gene Symbol: CACNA1A
1 Cross references
189 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 D

Ensembl ID : ENSOMYG00000011705
Gene Symbol: CACNA1D
1 Cross references
202 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 D

Ensembl ID : ENSOMYG00000044818
Gene Symbol: CACNA1D
1 Cross references
203 Possible Orthologues:

Cannabinoid Receptor 1

Ensembl ID : ENSOMYG00000001089
Gene Symbol: CNR1
1 Cross references
144 Possible Orthologues:

Cannabinoid Receptor 1

Ensembl ID : ENSOMYG00000033615
Gene Symbol: CNR1
1 Cross references
144 Possible Orthologues:

Cannabinoid Receptor 2

Ensembl ID : ENSOMYG00000009045
Gene Symbol: CNR2
1 Cross references
185 Possible Orthologues:

Cannabinoid Receptor 2

Ensembl ID : ENSOMYG00000036009
Gene Symbol: CNR2
1 Cross references
184 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).